Takeda weighs bidders for drug portfolio sale — 4 insights

Written by Eric Oliver | July 18, 2019 | Print  |

Takeda is looking to trim debt from its $59 billion purchase of Shire by selling portions of its drug portfolio in western Europe, Reuters reports.

What you should know:

1. Takeda wants to make 1.5 billion euros — $1.68 billion — from the sale.

2. The portfolio consists of over-the-counter and prescription medications where Takeda's patent has expired. Despite that, the portfolio has an EBITDA of around 160 million euros ($179.6 million).

3. Takeda retained the services of JPMorgan to find a buyer.

4. Takeda's acquisition of Shire put the company $52.73 billion in debt. To lower this, Takeda is attempting to sell $10 billion in assets.

More articles on surgery centers: 
6 surgery centers achieving total joint milestones
Regent Surgical Health, Conformis partner to cut ASC joint replacement costs
ASC total joint program bundles, vendors & more — 3 insights from an administrator

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.